Inicio › Cáncer de hígado (carcinoma hepatocelular) › Pensilvania › Philadelphia
Ensayos clínicos de Cáncer de hígado (carcinoma hepatocelular) en Philadelphia, PA
16 estudios para Cáncer de hígado (carcinoma hepatocelular) buscan participantes en centros de Philadelphia y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #98, Philadelphia
National Liver Cancer Screening Trial
ReclutandoFase 4
- University of Pennsylvania, Philadelphia
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
ReclutandoFase 3
- Research Site, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
ReclutandoFase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · A 23 mi de distancia
- Christiana Care Health System-Wilmington Hospital, Wilmington · A 25 mi de distancia
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
ReclutandoFase 2
- Thomas Jefferson University, Philadelphia
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Reclutando
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Y-90 Treatment Response Using Transarterial Radioembolization
ReclutandoFase 2
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
ReclutandoFase 1/2
- University of Pennsylvania, Philadelphia
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
ReclutandoFase 1/2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
ReclutandoFase 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SBRT With Atezo/Bev for HCC
ReclutandoFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
ReclutandoEstudio observacional
- Thomas Jefferson Hospital, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
ReclutandoFase 4
- Albert Einstein Healthcare Network, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Philadelphia
Ensayos de Cáncer de hígado (carcinoma hepatocelular) en otras ciudades
- Houston, TX31 estudios
- New York City, NY24 estudios
- Dallas, TX19 estudios
- Los Angeles, CA19 estudios
- Boston, MA18 estudios
- Cleveland, OH18 estudios
- Chicago, IL16 estudios
- Pittsburgh, PA15 estudios
- San Francisco, CA14 estudios
- Orange, CA14 estudios
- Jacksonville, FL14 estudios
- San Antonio, TX13 estudios
Otros estudios en Philadelphia
- Cáncer (todos los tipos)59 estudios
- Cáncer de seno56 estudios
- Cáncer de pulmón de células no pequeñas51 estudios
- Cáncer metastásico46 estudios
- Cáncer de próstata44 estudios
- Cáncer del colon y del recto44 estudios
- Cáncer de ovario44 estudios
- Cáncer de pulmón36 estudios
- Leucemia mielógena aguda34 estudios
- Fallo cardíaco31 estudios
- Cáncer de endometrio28 estudios
- Depresión26 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.